BioSpace News Archive

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced that the company will present its VISTA clinical program at the American Association for Cancer Research Annual Meeting 2023, to be held onsite in Orlando, Florida on April 14-19, 2023.

Helius Medical Technologies, Inc. and HealthTech Connex Inc. (“HTC”) announced today that they have entered into an exclusive distribution agreement.

Plus Therapeutics, Inc. today announced treatment of the first patient in Cohort 3 of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium ( 186 Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced financial and operating results for the year ended December 31, 2022.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., Executive Vice President and Chief Science Officer, presented data on the company’s PLACCINE platform at the Vaccine Technology Summit 2023 in Boston.

Acer Therapeutics Inc. announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company’s common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at the Investor Summit Conference being held virtually on March 29, 2023.

CND Life Sciences has entered into a licensing collaboration with Beth Israel Deaconess Medical Center (BIDMC) in Boston to advance CND’s scientific platform and patient-focused mission.